The effect of inofolic powder on fertility in women with polycystic ovary syndrome referred to the gynecology clinic

The effect of inofolic powder on fertility in women with polycystic ovaries

Clinical trial with control group, with parallel groups, randomized, and intervention group, with parallel groups, randomized,. Excel software rand function was used for randomization

In the control group, 50 infertile women with polycystic ovary syndrome are treated with metformin and progesterone on days 15 to 25 of the ovarian cycle. Also in the intervention group, 50 infertile women with polycystic ovary syndrome treated with metformin and progesterone on days 15 to 25 of the ovarian cycle, as well as inofolic powder in the form of two sachets per day throughout the month and the study site of the clinic Of women in Ilam province

Women with a history of clinical signs such as oligomenorrhea, irregular menstrual cycles and androgen-induced symptoms, tests and ultrasound confirmed polycystic ovary syndrome And have no confounding factors such as history of ovarian surgery in the last three months, use of antiepileptic drugs and glucocorticoids, congenital adrenal hyperplasia, hypothyroidism, hyperthyroidism

In the control group, 50 infertile women with polycystic ovary syndrome are treated with metformin and progesterone on days 15 to 25 of the ovarian cycle. Also in the intervention group, 50 infertile women with polycystic ovary syndrome are treated with metformin and progesterone on days 15 to 25 of the ovarian cycle, as well as inofolic powder in the form of two sachets per day throughout the month.

Inofolic powder is effective on fertility in women with polycystic ovaries and can increase the size and number of follicles.

In this study, due to the lack of access to patients and the lack of a database of patients with polycystic ovaries, it is not possible to select a sample randomly, therefore, within 3 months of attending the women's clinic and meeting the entry and exit criteria, as well as obtaining The satisfaction of the clients with the diagnosis of polycystic ovary samples is collected. Therefore, the selection of the sample at this stage will continue until the completion of the sample volume. Then we randomly assign one patient to the control group and one patient to the intervention group. Patients will not be aware of the assigned group, but they will be aware that they have entered a study and will sign a written consent form. Therefore, the allocation of the sample to the control and intervention groups will be completely random.